OTLKW Outlook Therapeutics Inc

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that C. Russell Trenary III, President and Chief Executive Officer of Outlook Therapeutics, will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.

A video webcast of the fireside chat will be available for viewing on-demand beginning Monday, January 10, 2022, at 7:00 AM ET for those registered for the conference and will be accessible on the Events page of the Investors section of the Outlook Therapeutics website, outlooktherapeutics.com.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:Media Inquiries:Harriet UllmanVice PresidentLaVoie Health ScienceT: 617-669-3082hullman@lavoiehealthscience.com

Investor Inquiries:       Jenene ThomasChief Executive OfficerJTC Team, LLCT: 833.475.8247 OTLK@jtcir.com